thiophenes has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (53.85) | 24.3611 |
| 2020's | 6 (46.15) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, SH; Liu, F; Meng, LQ; Tang, YX; Wang, SP; Wu, SQ; Xu, YG; Zhu, QH | 1 |
| Badisa, RB; Mack, N; Mazzio, E; Soliman, KFA | 1 |
| Gan, W; Guo, Q; Han, J; He, J; Jiang, Z; Li, Y; Liu, M; Liu, Y; Luo, L; Sun, C; Sun, X; Tang, S; Wu, Y; Xu, S; Yang, F; Yang, Y; Zhang, X; Zhu, W; Zuo, D | 1 |
| Armeson, K; Britten, C; Erlander, M; Ethier, S; Giordano, A; Kappler, C; Liu, Y; Park, Y; Reuben, J; Ridinger, M; Yeh, E | 1 |
| Bissanum, R; Kanokwiroon, K; Khongkow, M; Khongkow, P; Khunpitak, T; Ulhaka, K | 1 |
| Amirhossein Tabatabaei Dakhili, S; Bergman, C; Dufour, J; Juengling, FD; Pérez, DJ; Velázquez-Martínez, CA; Wuest, F; Wuest, M | 1 |
| Bachelet, CM; Corcé, V; Forté, J; Gontard, G; Rada, JP; Rey, NA; Salmain, M | 1 |
| Chanrion, M; Dewson, G; Geneste, O; Giner, G; Gong, JN; Gräsel, J; Herold, MJ; Huang, DCS; Lalaoui, N; Lessene, G; Li, X; Lindeman, GJ; Liu, K; Maragno, AL; Merino, D; Pal, B; Schneider, E; Segal, D; Serrano, A; Smyth, GK; Vaillant, F; Visvader, JE; Whittle, JR | 1 |
| Han, HH; He, XP; James, TD; Li, J; Wang, CZ; Zang, Y | 1 |
| Atwell, S; Brooks, HB; Dally, RD; Durham, TB; Fales, KR; Frimpong, K; Geeganage, S; Hui, YH; Konicek, SA; Lee, MR; Margolis, BJ; Mc Cowan, JR; Meier, TI; Njoroge, FG; Roth, KD; Shepherd, TA; Si, C; Thibodeaux, S; Thrasher, KJ; Torrado, A; Toth, JL; Wang, J; Wang, Y; Wu, Z | 1 |
| Bryant, C; Massey, AJ; Rawlinson, R | 1 |
| Burris, TP; Kojetin, D; Wang, Y | 1 |
| Green, JE; He, S; Min, DJ | 1 |
13 other study(ies) available for thiophenes and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
FDI-6 inhibits the expression and function of FOXM1 to sensitize BRCA-proficient triple-negative breast cancer cells to Olaparib by regulating cell cycle progression and DNA damage repair.
Topics: Cell Cycle; Cell Division; Cell Line, Tumor; DNA Damage; Forkhead Box Protein M1; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Pyridines; Thiophenes; Triple Negative Breast Neoplasms | 2021 |
Triple Isozyme Lactic Acid Dehydrogenase Inhibition in Fully Viable MDA-MB-231 Cells Induces Cytostatic Effects That Are Not Reversed by Exogenous Lactic Acid.
Topics: Cell Cycle; Cell Line, Tumor; Cell Survival; Cytostatic Agents; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Glycolysis; High-Throughput Screening Assays; Humans; Lactic Acid; Pyridones; Thiophenes; Triple Negative Breast Neoplasms; Tumor Microenvironment | 2021 |
XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epidermal Growth Factor; Humans; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Thiophenes; TOR Serine-Threonine Kinases; Triazines; Triple Negative Breast Neoplasms; Vimentin; Xenograft Model Antitumor Assays | 2022 |
Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Cycle Proteins; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Mice; Piperazines; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyrazoles; Quinazolines; Thiophenes; Triple Negative Breast Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
The Anticancer Effects of FDI-6, a FOXM1 Inhibitor, on Triple Negative Breast Cancer.
Topics: Antineoplastic Agents; Caspase 3; Cell Line, Tumor; Cell Movement; Female; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; Humans; Proto-Oncogene Proteins c-bcl-2; Pyridines; Thiophenes; Triple Negative Breast Neoplasms | 2021 |
FOXM1 Inhibitors as Potential Diagnostic Agents: First Generation of a PET Probe Targeting FOXM1 To Detect Triple-Negative Breast Cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Forkhead Box Protein M1; Humans; Mammary Neoplasms, Experimental; Mice; Molecular Structure; Positron-Emission Tomography; Pyridines; Structure-Activity Relationship; Thiophenes; Triple Negative Breast Neoplasms | 2021 |
Novel luminescent benzopyranothiophene- and BODIPY-derived aroylhydrazonic ligands and their dicopper(II) complexes: syntheses, antiproliferative activity and cellular uptake studies.
Topics: Antineoplastic Agents; Boron Compounds; Cell Line, Tumor; Copper; Female; Humans; Microscopy, Fluorescence; Molecular Structure; Thiophenes; Triple Negative Breast Neoplasms | 2021 |
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer.
Topics: Animals; bcl-2 Homologous Antagonist-Killer Protein; bcl-X Protein; Breast Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Gene Amplification; Humans; Lapatinib; Myeloid Cell Leukemia Sequence 1 Protein; Pyrimidines; Quinazolines; Receptor, ErbB-2; Survival Analysis; Taxoids; Thiophenes; Trastuzumab; Treatment Outcome; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Supramolecular core-glycoshell polythiophene nanodots for targeted imaging and photodynamic therapy.
Topics: Cell Line, Tumor; Fluorescent Dyes; HeLa Cells; Hep G2 Cells; Humans; Liver Neoplasms; Macromolecular Substances; Molecular Structure; Nanoparticles; Optical Imaging; Particle Size; Photochemotherapy; Polymers; Thiophenes; Triple Negative Breast Neoplasms | 2017 |
Discovery of N-(6-Fluoro-1-oxo-1,2-dihydroisoquinolin-7-yl)-5-[(3R)-3-hydroxypyrrolidin-1-yl]thiophene-2-sulfonamide (LSN 3213128), a Potent and Selective Nonclassical Antifolate Aminoimidazole-4-carboxamide Ribonucleotide Formyltransferase (AICARFT) Inhi
Topics: Animals; Antineoplastic Agents; Breast; Cell Line, Tumor; Cell Proliferation; Drug Discovery; Female; Folic Acid Antagonists; Humans; Male; Mice; Mice, Nude; Models, Molecular; Phosphoribosylaminoimidazolecarboxamide Formyltransferase; Sulfonamides; Thiophenes; Triple Negative Breast Neoplasms | 2017 |
Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
Topics: Benzodiazepinones; Biomarkers, Tumor; Cell Line, Tumor; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Indoles; MCF-7 Cells; Ovarian Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyridones; Thiophenes; Triple Negative Breast Neoplasms; Urea | 2014 |
Anti-proliferative actions of a synthetic REV-ERBα/β agonist in breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin A; Female; Humans; Nuclear Receptor Subfamily 1, Group D, Member 1; Pyrrolidines; Receptor, ErbB-2; Receptors, Estrogen; Thiophenes; Triple Negative Breast Neoplasms | 2015 |
Birinapant (TL32711) Improves Responses to GEM/AZD7762 Combination Therapy in Triple-negative Breast Cancer Cell Lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; Dipeptides; DNA Repair; Female; Gemcitabine; Humans; Indoles; Phosphorylation; Thiophenes; Triple Negative Breast Neoplasms; Urea | 2016 |